Triple-Negative Breast Cancer

The deregulation of ubiquitin-specific protease 7 activity increased DNA replication stress in an in vitro study, which was found to disrupt the DNA repair process during the S phase of the cell cycle. Aberrant expression of ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme, is involved in tumor progression. This is due to altered DNA damage...

Saraca asoca methanol bark extract had a selective anticancer effect on the estrogen-receptor subtype of triple-negative breast cancer in a cell culture study. The anticancer effects were attributed to phytoestrogens in the methanol bark extract, particularly quercetin. Saraca asoca has been found to have anticancer effects related to the presence of phytoestrogens in the methanol...

17ß-estradiol promotes metastasis in patients with triple-negative breast cancer. A cell culture and mouse model study demonstrated that this process may be mediated by the calpain/YAP/ß-catenin signaling axis. The absence of estrogen and progesterone receptors and human epidermal growth factor receptor-2 characterizes triple-negative breast cancer (TNBC) cells. The estrogen 17ß-estradiol, or E2, promotes the proliferation...

The type of adjuvant systemic therapy has an impact on Edmonton Symptom Assessment System scores in patients with breast cancer, as reported in a recent retrospective analysis. Triple-negative tumor histology and the outcomes of previous neoadjuvant treatment were related to symptom burden. Multimodal treatment in breast cancer patients can have side effects, as reported in...

Salvianolic acid A, an anti-cancer agent, showed a potential effect on M2 tumor-associated macrophages in a cell culture study, which concluded that it may be useful for reprogramming these macrophages in the management of triple-negative breast cancer. Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with challenging management and a poor prognosis....

Selinexor in combination with venetoclax and azacitidine (the SAV regimen) is safe and effective, with encouraging complete response rates, according to a recent prospective study. Acute myeloid leukemia (AML) primarily affects older people, who are frequently unable to endure intense chemotherapy due to frailty or comorbid conditions. While venetoclax with azacytidine has a 64% response...

Atezolizumab therapy for advanced or metastatic triple-negative breast cancer (TNBC) was found to have a similar safety profile to those of previous trials and was associated with changes to the immune system in a recent retrospective study.  Triple-negative breast cancer (TNBC) refers to breast tumors that lack hormone receptors (HR) and human epidermal growth factor...

Triple-negative breast cancer patients treated with immune checkpoint inhibitors may experience a greater antitumoral immune response, according to a recent literature review. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized solid tumor malignancy treatment. ICIs target immunosuppressive receptors such as programmed cell death ligand 1 (PD-L1), programmed cell death 1 (PD-1), and cytotoxic T-lymphocyte-associated protein...

Obesity is a risk factor for cancer recurrence in resected hormone-sensitive breast cancer patients undergoing adjuvant chemotherapy with aromatase inhibitors, according to a recent study. Aromatase inhibitors (AIs) are extensively used for treating hormone-sensitive breast cancer (BC). In post-menopause, estrogen is mainly formed in the adipose tissue via aromatase-mediated androgen conversion, which might impair the...